Published in J Biol Chem on October 26, 2010
Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat Commun (2015) 1.37
Mutant TP53 posttranslational modifications: challenges and opportunities. Hum Mutat (2014) 0.91
Further evidence for pathogenicity of the TP53 tetramerization domain mutation p.Arg342Pro in Li-Fraumeni syndrome. Fam Cancer (2015) 0.79
Fuse binding protein antagonizes the transcription activity of tumor suppressor protein p53. BMC Cancer (2014) 0.77
Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers. Nucleic Acids Res (2014) 0.76
Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. Cold Spring Harb Mol Case Stud (2016) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol (1993) 64.61
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 12.98
An oncogene-induced DNA damage model for cancer development. Science (2008) 11.60
Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol (2003) 8.42
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev (1998) 7.78
The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev (2000) 5.72
p53 and human cancer: the first ten thousand mutations. Adv Cancer Res (2000) 4.71
A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J (1999) 4.68
Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A (2003) 4.06
Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science (1995) 3.69
In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res (1996) 3.50
p53 polymorphisms: cancer implications. Nat Rev Cancer (2009) 3.33
Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat Struct Biol (1995) 2.75
Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol (2009) 2.34
Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J (1993) 2.21
iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet (2006) 2.20
The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol (2007) 2.13
Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol (2009) 2.10
A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol (2002) 1.80
Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry (1997) 1.66
The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol (2010) 1.64
Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc Natl Acad Sci U S A (2007) 1.56
Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain. J Biol Chem (2008) 1.55
The role of tetramerization in p53 function. Oncogene (2001) 1.53
Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat (2005) 1.46
Regulation of p53 tetramerization and nuclear export by ARC. Proc Natl Acad Sci U S A (2007) 1.41
Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain. EMBO J (1998) 1.39
14-3-3 activation of DNA binding of p53 by enhancing its association into tetramers. Nucleic Acids Res (2008) 1.36
Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J Biol Chem (1999) 1.33
Molecular basis of Pirh2-mediated p53 ubiquitylation. Nat Struct Mol Biol (2008) 1.32
Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome. Oncogene (1998) 1.31
The p53 mutation "gradient effect" and its clinical implications. J Cell Physiol (2007) 1.28
Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members. Oncogene (1998) 1.28
Thermodynamic analysis of the structural stability of the tetrameric oligomerization domain of p53 tumor suppressor. Biochemistry (1995) 1.26
Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers. J Biol Chem (2009) 1.25
Fibrillar aggregates of the tumor suppressor p53 core domain. Biochemistry (2003) 1.22
The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library. Oncogene (2005) 1.20
Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle (2006) 1.15
Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins. Acc Chem Res (2010) 1.06
p53 Oligomerization is essential for its C-terminal lysine acetylation. J Biol Chem (2008) 1.06
Cellular dimensions affecting the nucleocytoplasmic volume ratio. J Cell Biol (1991) 1.04
Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer. Biochemistry (2006) 0.98
Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization. Mol Cell Biol (2000) 0.95
The (1-63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies. Biophys J (2008) 0.90
The oligomerization domain of p53: crystal structure of the trigonal form. FEBS Lett (1996) 0.88
Tandem dimerization of the human p53 tetramerization domain stabilizes a primary dimer intermediate and dramatically enhances its oligomeric stability. J Mol Biol (2006) 0.87
Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain. Int J Cancer (1998) 0.84
Influence of tetramerisation on site-specific post-translational modifications of p53: comparison of human and murine p53 tumor suppressor protein. Cancer Biol Ther (2008) 0.84
Function, oligomerization, and conformation of tumor-associated p53 proteins with mutated C-terminus. J Cell Biochem (2000) 0.82
Evaluation of transcriptional activity of p53 in individual living mammalian cells. Anal Biochem (2009) 0.81
Oxidation of methionine residue at hydrophobic core destabilizes p53 tetrameric structure. Biopolymers (2009) 0.81
Fast, qualitative analysis of p53 phosphorylation by protein kinases. Biotechniques (2000) 0.77
Parallel analysis of tetramerization domain mutants of the human p53 protein using PCR colonies. Genomic Med (2007) 0.76
Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet (2004) 3.89
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J (2002) 3.45
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet (2002) 3.32
Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell (2006) 2.39
Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol (2009) 2.34
Distinct p53 genomic binding patterns in normal and cancer-derived human cells. Cell Cycle (2011) 2.01
Mutation of mouse p53 Ser23 and the response to DNA damage. Mol Cell Biol (2002) 1.65
Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem (2003) 1.63
Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. Cell Cycle (2009) 1.57
ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J Biol Chem (2002) 1.56
Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J Exp Med (2006) 1.53
The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J Virol (2002) 1.45
Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol Cell Biol (2006) 1.45
Pillars article: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992. 255: 1261-1263. J Immunol (2007) 1.39
Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells. Nucleic Acids Res (2013) 1.33
Substrate specificity of the human protein phosphatase 2Cdelta, Wip1. Biochemistry (2005) 1.23
Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1. Biochemistry (2006) 1.06
The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases. Biochemistry (2007) 1.04
Gamma interferon triggers interaction between ICSBP (IRF-8) and TEL, recruiting the histone deacetylase HDAC3 to the interferon-responsive element. Mol Cell Biol (2002) 1.03
PPM1D430, a novel alternative splicing variant of the human PPM1D, can dephosphorylate p53 and exhibits specific tissue expression. J Biochem (2008) 1.03
Differential recognition of phosphorylated transactivation domains of p53 by different p300 domains. J Mol Biol (2007) 1.01
The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX. DNA Repair (Amst) (2004) 1.01
Induction of PPM1D following DNA-damaging treatments through a conserved p53 response element coincides with a shift in the use of transcription initiation sites. Nucleic Acids Res (2008) 1.01
Paired-end genomic signature tags: a method for the functional analysis of genomes and epigenomes. Genet Eng (N Y) (2007) 0.99
Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer. Biochemistry (2006) 0.98
SMAR1 forms a ternary complex with p53-MDM2 and negatively regulates p53-mediated transcription. J Mol Biol (2009) 0.96
Thr-774 (transmembrane segment M5), Val-920 (M8), and Glu-954 (M9) are involved in Na+ transport, and Gln-923 (M8) is essential for Na,K-ATPase activity. J Biol Chem (2005) 0.93
Mutant TP53 posttranslational modifications: challenges and opportunities. Hum Mutat (2014) 0.91
Design of potent inhibitors of human RAD51 recombinase based on BRC motifs of BRCA2 protein: modeling and experimental validation of a chimera peptide. J Med Chem (2010) 0.89
A small molecule inhibitor of p53-inducible protein phosphatase PPM1D. Bioorg Med Chem Lett (2011) 0.86
Effect of phosphorylation on the structure and fold of transactivation domain of p53. J Biol Chem (2002) 0.85
Post-aggregation oxidation of mutant huntingtin controls the interactions between aggregates. J Biol Chem (2012) 0.83
Evidence for a relationship between activity and the tetraprotomeric assembly of solubilized pig gastric H/K-ATPase. J Biochem (2005) 0.82
Characterization of the active site and a unique uncompetitive inhibitor of the PPM1-type protein phosphatase PPM1D. Protein Pept Lett (2008) 0.82
Evaluation of transcriptional activity of p53 in individual living mammalian cells. Anal Biochem (2009) 0.81
Oxidation of methionine residue at hydrophobic core destabilizes p53 tetrameric structure. Biopolymers (2009) 0.81
Enhancement of transcriptional activity of mutant p53 tumor suppressor protein through stabilization of tetramer formation by calix[6]arene derivatives. Bioorg Med Chem Lett (2010) 0.80
Fluoroalkene modification of mercaptoacetamide-based histone deacetylase inhibitors. Bioorg Med Chem (2009) 0.78
Drastic effects on fibril formation of amyloid-beta peptides by the addition of amino acid residue units to the termini. Protein Pept Lett (2010) 0.77
Phosphatase assay for multi-phosphorylated substrates using phosphatase specific-motif antibody. J Biochem (2011) 0.76
Structural isoforms of the circadian neuropeptide PDF expressed in the optic lobes of the cricket Gryllus bimaculatus: immunocytochemical evidence from specific monoclonal antibodies. J Comp Neurol (2006) 0.76
Dynamic interactions of proteins in complex networks. FEBS J (2009) 0.76
Compensation, crosstalk and sequestering: the currency of checkpoints in cancer. Cell Cycle (2013) 0.76
Effects of biomineralization peptide topology on the structure and catalytic activity of Pd nanomaterials. Chem Commun (Camb) (2014) 0.76
Identifying protein interactions. FEBS J (2005) 0.75
Probing phenylalanine environments in oligomeric structures with pentafluorophenylalanine and cyclohexylalanine. Biopolymers (2011) 0.75
Effects of tumor-associated mutations in the p53 tetramerization domain on oligomerization state and transcriptional activity. Adv Exp Med Biol (2009) 0.75
Clinical evaluation of osseointegrated implants in Tokyo Dental College Hospital (third report): long-term observation of functioning survival rate of fixtures. Bull Tokyo Dent Coll (2003) 0.75
[Tetramerization of tumor suppressor protein p53]. Seikagaku (2010) 0.75
New evidence for ATP binding induced catalytic subunit interactions in pig kidney Na/K-ATPase. J Biochem (2006) 0.75
Inhibition of tumor suppressor protein p53-dependent transcription by a tetramerization domain peptide via hetero-oligomerization. Bioorg Med Chem Lett (2012) 0.75
Formation process and solvent-dependent structure of a polyproline self-assembled monolayer on a gold surface. Langmuir (2011) 0.75
Structural requirements of nociceptin antagonist Ac-RYYRIK-NH2 for receptor binding. J Pept Sci (2002) 0.75
[Function of Proto-oncogene Product PPM1D and Development of PPM1D Inhibitors for Cancer Chemotherapy]. Seikagaku (2015) 0.75